Skip to content
Home › 13F recaps › Q3 2026 › VRTX

Which funds bought or sold VRTX in Q3 2026?

Vertex Pharmaceuticals Inc. 5 funds bought, 6 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$701M.

Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)

PostLinkedIn
Who bought and who sold VRTX, by estimated dollars
◀ SoldBought ▶

Top 10 each side. NEW = opened a position, OUT = sold the whole position.

Bought (5)

FundChangeEst. $Now
Jennison
Growth / crossover
Added+19.2%+$300M$1.9B
Citadel
Quant & multi-strategy
Added+102.3%+$273M$540M
CPP Investments
Sovereign & pension
Added+53.9%+$100M$286M
Northern Trust
Bank & broker
Added+3.2%+$41M$1.3B
CalPERS
Sovereign & pension
Added+8.4%+$20M$254M

Sold (6)

FundChangeEst. $Now
Capital Research
Asset manager
Trimmed-8.6%−$876M$9.3B
JPMorgan
Bank & broker
Trimmed-12.7%−$435M$3.0B
Ameriprise
Asset manager
Trimmed-13.1%−$178M$1.2B
Schwab
Index giant
Trimmed-8.1%−$86M$981M
Adage
Hedge fund
Trimmed-32.4%−$67M$139M
Hudson Bay
Quant & multi-strategy
Trimmed-29.8%−$61M$143M

Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.

Most bought in Q3 2026 → · Most sold →

Weekly digest · free

13F filings and guru moves, in one short email

A Sunday digest of what famous investors said and filed this week, plus an alert when someone changes stance. Free, no spam, unsubscribe anytime.